Institution
Wayne State University
Education•Detroit, Michigan, United States•
About: Wayne State University is a education organization based out in Detroit, Michigan, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 42801 authors who have published 82738 publications receiving 3083713 citations. The organization is also known as: WSU & Wayne University.
Topics: Population, Cancer, Poison control, Pregnancy, Medicine
Papers published on a yearly basis
Papers
More filters
Indiana University1, Pasteur Institute2, Washington University in St. Louis3, University of British Columbia4, Cubist Pharmaceuticals5, University of Turku6, Lahey Hospital & Medical Center7, Harvard University8, University of Medicine and Dentistry of New Jersey9, The Evergreen State College10, Wayne State University11, Tufts University12, Northeastern University13, University of California, Los Angeles14, University of Notre Dame15, University of Birmingham16, MedImmune17, Rockefeller University18, Université catholique de Louvain19, Cardiff University20, Cold Spring Harbor Laboratory21, Robert Koch Institute22, McMaster University23, University of Oklahoma24
TL;DR: To explore how the problem of antibiotic resistance might best be addressed, a group of 30 scientists from academia and industry gathered at the Banbury Conference Centre in Cold Spring Harbor, New York, USA, from 16 to 18 May 2011.
Abstract: The development and spread of antibiotic resistance in bacteria is a universal threat to both humans and animals that is generally not preventable but can nevertheless be controlled, and it must be tackled in the most effective ways possible. To explore how the problem of antibiotic resistance might best be addressed, a group of 30 scientists from academia and industry gathered at the Banbury Conference Centre in Cold Spring Harbor, New York, USA, from 16 to 18 May 2011. From these discussions there emerged a priority list of steps that need to be taken to resolve this global crisis.
929 citations
Memorial Sloan Kettering Cancer Center1, Cleveland Clinic2, Harvard University3, University of Michigan4, Northwestern University5, Duke University6, Wayne State University7, Medical University of South Carolina8, Roswell Park Cancer Institute9, Indiana University10, Stanford University11, Fox Chase Cancer Center12, Bristol-Myers Squibb13, Johns Hopkins University14
TL;DR: Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC, and no dose-response relationship was detected as measured by PFS.
Abstract: Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Patients and Methods Patients with clear-cell mRCC previously treated with agents targeting the vascular endothelial growth factor pathway were randomly assigned (blinded ratio of 1:1:1) to nivolumab 0.3, 2, or 10 mg/kg intravenously once every 3 weeks. The primary objective was to evaluate the dose-response relationship as measured by progression-free survival (PFS); secondary end points included objective response rate (ORR), overall survival (OS), and safety. Results A total of 168 patients were randomly assigned to the nivolumab 0.3- (n = 60), 2- (n = 54), and 10-mg/kg (n = 54) cohorts. One hundred eighteen patients (70%) had received more than one prior systemic regimen. Median PFS was 2.7, 4.0, a...
923 citations
SUNY Downstate Medical Center1, McGill University2, University of Connecticut3, Cornell University4, Umeå University5, Wayne State University6, University of Iowa7, University of Miami8, University of Pennsylvania9, Mayo Clinic10, University of Sydney11, University of Buenos Aires12, University of Chicago13, Shanghai Jiao Tong University14, North-West University15, University of Rochester16, University of Glasgow17, Virginia Commonwealth University18, University of Melbourne19
TL;DR: Clinical Practice Guidelines for the Management of Hypertension in the Community as mentioned in this paper A Statement by the American Society of hypertension and the International Society of Hyperpharmension (ISH).
Abstract: Clinical Practice Guidelines for the Management of Hypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hypertension
920 citations
TL;DR: Surgery has largely supplanted radiation therapy as the primary treatment modality for anal cancer, especially when there is a chance for cure, and these lesions, which lie in close relationship to the dentate line, are neoplasms with rapid growth characteristics.
Abstract: IN COMPARISON with adenocarcinoma of the rectum, anal cancer is uncommon. 2 According to Morson, a one squamous-cell cancer is seen for every 28 rectal adenocarcinomas, an incidence of about .'4.5 per cent. As a consequence, individual experience with anal cancer is limited. Fortunately, several recent collective reviews provide guidelines for treatment. 4, s Surgery has largely supplanted radiation therapy as the primary treatment modality for anal cancer, especially when there is a chance for cure. Local excision is usually done for cancer of the anal margin, while resection of the rectum is the preferred treatment for cancer of the anal canal. Resuhs of surgical treatment o~ cancer of the anal margin are good, since the lesions are usually well differentiated, but this is not the case with cancer of the anal canal. These lesions, which lie in close relationship to the dentate line, are neoplasms with rapid growth characteristics. They are highly anaplastic squamous cancers with various cell types sometimes described in terms such as "transitional," "basaloid," or "cloacogenic." These tunaors generally have a poor prognosis.a
920 citations
Book•
19 May 2005TL;DR: In this article, the authors present a detailed review of liquid sloshing dynamics in rigid containers, including linear forced and non-linear interaction under external and parametric excitations.
Abstract: Preface Introduction 1. Fluid field equations and modal analysis in rigid containers 2. Linear forced sloshing 3. Viscous damping and sloshing suppression devices 4. Weakly nonlinear lateral sloshing 5. Equivalent mechanical models 6. Parametric sloshing (Faraday's waves) 7. Dynamics of liquid sloshing impact 8. Linear interaction of liquid sloshing with elastic containers 9. Nonlinear interaction under external and parametric excitations 10. Interactions with support structures and tuned sloshing absorbers 11. Dynamics of rotating fluids 12. Microgravity sloshing dynamics Bibliography Index.
920 citations
Authors
Showing all 43073 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Robert Langer | 281 | 2324 | 326306 |
| Eugene Braunwald | 230 | 1711 | 264576 |
| Rakesh K. Jain | 200 | 1467 | 177727 |
| Anil K. Jain | 183 | 1016 | 192151 |
| Richard A. Gibbs | 172 | 889 | 249708 |
| Bradley Cox | 169 | 2150 | 156200 |
| Jun Wang | 166 | 1093 | 141621 |
| David Altshuler | 162 | 345 | 201782 |
| Elliott M. Antman | 161 | 716 | 179462 |
| Jovan Milosevic | 152 | 1433 | 106802 |
| Roberto Romero | 151 | 1516 | 108321 |
| Kypros H. Nicolaides | 147 | 1302 | 87091 |
| John F. Hartwig | 145 | 714 | 66472 |
| Charles Maguire | 142 | 1197 | 95026 |
| Mingshui Chen | 141 | 1543 | 125369 |